Drug Profile
Pentacea
Latest Information Update: 08 Aug 2005
Price :
$50
*
At a glance
- Originator IBC Pharmaceuticals
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Small cell lung cancer
Most Recent Events
- 08 Aug 2005 No development reported - Phase-II for Small cell lung cancer in USA (Injection)
- 17 Jun 2002 Immunomedics has acquired Beckman Coulter's interest in their joint venture IBC Pharmaceuticals
- 15 Mar 2000 Phase-II clinical trials for Small cell lung cancer in USA (Injection)